| Newsletter |
Subject |
| Vol. 21 No. 9 |
Global Visionaries and Giants
|
| Vol. 21 No. 8 |
Embracing the Future of Pharmaceutical Compounding
|
| Vol. 21 No. 7 |
IJPC July/August Issue
|
| Vol. 21 No. 6 |
The IJPC Compounders' Network List (CNL)
|
| Vol. 21 No. 5 |
IJPC May/June Issue
|
| Vol. 21 No. 4 |
Compounding Pharmacies Are a National Treasure
|
| Vol. 21 No. 3 |
IJPC March/April Issue
|
| Vol. 21 No. 2 |
United States Pharmacopoeia 101, Part 13
|
| Vol. 21 No. 1 |
IJPC January/February Issue
|
| Vol. 20 No. 49 |
Merry Christmas from IJPC
|
| Vol. 20 No. 48 |
Finding What You Need on IJPC.com
|
| Vol. 20 No. 47 |
The Compounders' Network List
|
| Vol. 20 No. 46 |
IJPC's Themed Archives
|
| Vol. 20 No. 45 |
IJPC November-December 2023 Table of Contents
|
| Vol. 20 No. 44 |
Veterans Day
|
| Vol. 20 No. 43 |
The CompoundingToday Physicochemical Database
|
| Vol. 20 No. 42 |
United States Pharmacopeia <101>, Part 12
|
| Vol. 20 No. 41 |
IJPC September-October 2023 Table of Contents
|
| Vol. 20 No. 40 |
IJPC is Going Digital!
|
| Vol. 20 No. 39 |
United States Pharmacopeia <101>, Part 11
|
| Vol. 20 No. 38 |
United States Pharmacopeia <101>, Part 10 - Glossary
|
| Vol. 20 No. 37 |
United States Pharmacopeia <101>, Part 9
|
| Vol. 20 No. 36 |
Larry Trissel - Obituary
|
| Vol. 20 No. 35 |
United States Pharmacopeia <101>, Part 8
|
| Vol. 20 No. 34 |
United States Pharmacopeia <101>, Part 7
|
| Vol. 20 No. 33 |
United States Pharmacopeia <101>, Part 6
|
| Vol. 20 No. 32 |
United States Pharmacopeia <101>, Part 5
|
| Vol. 20 No. 31 |
United States Pharmacopeia <101>, Part 4
|
| Vol. 20 No. 30 |
United States Pharmacopeia <101>, Part 3
|
| Vol. 20 No. 29 |
United States Pharmacopeia <101>, Part 2B
|
| Vol. 20 No. 28 |
United States Pharmacopeia <101>, Part 2A
|
| Vol. 20 No. 27 |
United States Pharmacopeia <101>, Part 1
|
| Vol. 20 No. 26 |
Celebrate Independence Day!
|
| Vol. 20 No. 25 |
Drug Shortage Update and Resources
|
| Vol. 20 No. 24 |
Happy Father's Day!
|
| Vol. 20 No. 23 |
Online Archive Access for IJPC Subscribers
|
| Vol. 20 No. 22 |
Glossary of terms from FDA
|
| Vol. 20 No. 21 |
Memorial Day
|
| Vol. 20 No. 20 |
For the Graduate
|
| Vol. 20 No. 19 |
Happy Mother's Day
|
| Vol. 20 No. 18 |
Compounding and the FDA: Questions and Answers
|
| Vol. 20 No. 17 |
IJPC May-June 2023 Table of Contents
|
| Vol. 20 No. 16 |
FDA Guidance for Industry Document #256 - Compounding Animal Drugs from Bulk Drug Substances - Part 5
|
| Vol. 20 No. 15 |
FDA Guidance for Industry Document #256 - Compounding Animal Drugs from Bulk Drug Substances - Part 4
|
| Vol. 20 No. 14 |
FDA Guidance for Industry Document #256 - Compounding Animal Drugs from Bulk Drug Substances - Part 3
|
| Vol. 20 No. 13 |
FDA Guidance for Industry Document #256 - Compounding Animal Drugs from Bulk Drug Substances - Part 2
|
| Vol. 20 No. 12 |
FDA Guidance for Industry Document #256 - Compounding Animal Drugs from Bulk Drug Substances - Part 1
|
| Vol. 20 No. 11 |
IJPC Mar/Apr 2023 Table of Contents
|
| Vol. 20 No. 10 |
Part 3 of Ibuprofen Oral Suspension Guidance from the FDA
|
| Vol. 20 No. 9 |
Part 2 of Ibuprofen Oral Suspension Guidance from the FDA
|
| Vol. 20 No. 8 |
Ibuprofen Oral Suspension Guidance from the FDA
|
| Vol. 20 No. 7 |
Compounding for Terrorist Attacks and Natural Disasters: Part 2
|
| Vol. 20 No. 6 |
Compounding for Terrorist Attacks and Natural Disasters: Part 1
|
| Vol. 20 No. 5 |
IJPC Jan/Feb 2023 Issue Available
|
| Vol. 20 No. 4 |
FDA Beta-Lactum Shortage Guidance Discussion
|
| Vol. 20 No. 3 |
Are the Compounding Gods Listening?
|
| Vol. 20 No. 2 |
FDA Beta-Lactum Shortage Guidance
|
| Vol. 20 No. 1 |
Amoxicillin Shortage Continues: Compounding Pharmacies Filling the Gap!
|
| Vol. 19 No. 50 |
Happy New Year from IJPC!
|
| Vol. 19 No. 49 |
Amoxicillin Shortage Worsens to 44 Products, Resupply Dates Pushed to 2023
|
| Vol. 19 No. 48 |
FDA Guidance for Industry - Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules
|
| Vol. 19 No. 47 |
FDA Guidance for Industry - Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules
|
| Vol. 19 No. 46 |
FDA Guidance for Industry - Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules
|
| Vol. 19 No. 45 |
A Review of the Revised United States Pharmacopeia <797>
|
| Vol. 19 No. 44 |
IJPC November/December 2022 Table of Contents
|
| Vol. 19 No. 43 |
FDA Guidance for Industry Practices
|
| Vol. 19 No. 42 |
FDA Good Guidance Practices, Part 8
|
| Vol. 19 No. 41 |
FDA Good Guidance Practices, Part 7
|
| Vol. 19 No. 40 |
The FDA and Desiccated Thyroid Extract
|
| Vol. 19 No. 39 |
FDA Good Guidance Practices, Part 6
|
| Vol. 19 No. 38 |
FDA Good Guidance Practices, Part 5
|
| Vol. 19 No. 37 |
FDA Good Guidance Practices, Part 4
|
| Vol. 19 No. 36 |
FDA Good Guidance Practices, Part 3
|
| Vol. 19 No. 35 |
FDA Good Guidance Practices, Part 2
|
| Vol. 19 No. 34 |
FDA Good Guidance Practices, Part 1
|
| Vol. 19 No. 33 |
IJPC September/October 2022 Table of Contents
|
| Vol. 19 No. 32 |
Cosmetics for Special Populations and for Use as Compounding Vehicles, Part 9
|
| Vol. 19 No. 31 |
Cosmetics for Special Populations and for Use as Compounding Vehicles, Part 8
|
| Vol. 19 No. 30 |
Cosmetics for Special Populations and for Use as Compounding Vehicles, Part 7
|
| Vol. 19 No. 29 |
Cosmetics for Special Populations and for Use as Compounding Vehicles, Part 6
|
| Vol. 19 No. 28 |
Cosmetics for Special Populations and for Use as Compounding Vehicles, Part 5
|
| Vol. 19 No. 27 |
Cosmetics for Special Populations and for Use as Compounding Vehicles, Part 4
|
| Vol. 19 No. 26 |
Cosmetics for Special Populations and for Use as Compounding Vehicles, Part 3
|
| Vol. 19 No. 25 |
IJPC July/August 2022 Table of Contents
|
| Vol. 19 No. 24 |
Cosmetics for Special Populations and for Use as Compounding Vehicles, Part 2
|
| Vol. 19 No. 23 |
Cosmetics for Special Populations and for Use as Compounding Vehicles
|
| Vol. 19 No. 22 |
Compounding for Terrorist Attacks, Wars, and Natural Disasters: Part 6
|
| Vol. 19 No. 21 |
Compounding for Terrorist Attacks, Wars, and Natural Disasters: Part 5
|
| Vol. 19 No. 20 |
Compounding for Terrorist Attacks, Wars, and Natural Disasters: Part 4
|
| Vol. 19 No. 19 |
IJPC May/June 2022 Table of Contents
|
| Vol. 19 No. 18 |
Compounding for Terrorist Attacks, Wars, and Natural Disasters: Part 3
|
| Vol. 19 No. 17 |
Compounding for Terrorist Attacks, Wars, and Natural Disasters: Part 2
|
| Vol. 19 No. 16 |
Compounding for Terrorist Attacks, Wars, and Natural Disasters: Part 1
|
| Vol. 19 No. 15 |
Experts and Errors!
|
| Vol. 19 No. 14 |
Pharmaceutical Compounding Errors, Part 11 (Final)
|
| Vol. 19 No. 13 |
Pharmaceutical Compounding Errors, Part 10
|
| Vol. 19 No. 12 |
IJPC March/April 2022 Table of Contents
|
| Vol. 19 No. 11 |
Pharmaceutical Compounding Errors, Part 9
|
| Vol. 19 No. 10 |
Pharmaceutical Compounding Errors, Part 8
|
| Vol. 19 No. 9 |
Pharmaceutical Compounding Errors, Part 7
|
| Vol. 19 No. 8 |
Pharmaceutical Compounding Errors, Part 6
|
| Vol. 19 No. 7 |
Pharmaceutical Compounding Errors, Part 5
|
| Vol. 19 No. 6 |
Pharmaceutical Compounding Errors, Part 4 (Corrected)
|
| Vol. 19 No. 5 |
Pharmaceutical Compounding Errors, Part 4
|
| Vol. 19 No. 4 |
Pharmaceutical Compounding Errors, Part 3
|
| Vol. 19 No. 3 |
Pharmaceutical Compounding Errors, Part 2
|
| Vol. 19 No. 2 |
Pharmaceutical Compounding Errors
|
| Vol. 19 No. 1 |
IJPC January/February 2022 Table of Contents
|
| Vol. 18 No. 51 |
Happy New Year!
|
| Vol. 18 No. 50 |
Merry Christmas from IJPC!
|
| Vol. 18 No. 49 |
Just in! Scientific American Article (December 2021) Supporting Patient-Specific Medications!
|
| Vol. 18 No. 48 |
Pharmaceutical Compounding Errors: Sources and Prevention, Part 1
|
| Vol. 18 No. 47 |
Don't Forget to "Keep Up" During the Holidays
|
| Vol. 18 No. 46 |
Happy Thanksgiving!
|
| Vol. 18 No. 45 |
IJPC November/December 2021 Table of Contents
|
| Vol. 18 No. 44 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 16
|
| Vol. 18 No. 43 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 15
|
| Vol. 18 No. 42 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 14
|
| Vol. 18 No. 41 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 13
|
| Vol. 18 No. 40 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 12
|
| Vol. 18 No. 39 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 11
|
| Vol. 18 No. 38 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 10
|
| Vol. 18 No. 37 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 9
|
| Vol. 18 No. 36 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 8
|
| Vol. 18 No. 35 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 7
|
| Vol. 18 No. 34 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 6
|
| Vol. 18 No. 33 |
IJPC September/October 2021 Table of Contents
|
| Vol. 18 No. 32 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 5
|
| Vol. 18 No. 31 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 4
|
| Vol. 18 No. 30 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 3
|
| Vol. 18 No. 29 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 2
|
| Vol. 18 No. 28 |
The FDA and Pharmacy Compounding - FDA Form 483, Part 1
|
| Vol. 18 No. 27 |
IJPC July/August 2021 Table of Contents
|
| Vol. 18 No. 26 |
The FDA, Part 13
|
| Vol. 18 No. 25 |
The FDA, Part 12
|
| Vol. 18 No. 24 |
The FDA, Part 11
|
| Vol. 18 No. 23 |
The FDA, Part 10
|
| Vol. 18 No. 22 |
IJPC May/June 2021 Table of Contents
|
| Vol. 18 No. 21 |
The FDA, Part 9
|
| Vol. 18 No. 20 |
The FDA, Part 8
|
| Vol. 18 No. 19 |
The FDA, Part 7
|
| Vol. 18 No. 18 |
The FDA, Part 6
|
| Vol. 18 No. 17 |
The FDA, Part 5
|
| Vol. 18 No. 16 |
The FDA, Part 4
|
| Vol. 18 No. 15 |
The FDA, Part 3
|
| Vol. 18 No. 14 |
The FDA, Part 2
|
| Vol. 18 No. 13 |
The FDA, Part 1
|
| Vol. 18 No. 12 |
IJPC March/April 2021 Table of Contents
|
| Vol. 18 No. 11 |
Insanitary Conditions at Compounding Facilities, Part 8
|
| Vol. 18 No. 10 |
Insanitary Conditions at Compounding Facilities, Part 7
|
| Vol. 18 No. 9 |
Insanitary Conditions at Compounding Facilities, Part 6
|
| Vol. 18 No. 8 |
Insanitary Conditions at Compounding Facilities, Part 5
|
| Vol. 18 No. 7 |
Insanitary Conditions at Compounding Facilities, Part 4
|
| Vol. 18 No. 6 |
Insanitary Conditions at Compounding Facilities, Part 3
|
| Vol. 18 No. 5 |
Insanitary Conditions at Compounding Facilities, Part 2
|
| Vol. 18 No. 4 |
Insanitary Conditions at Compounding Facilities
|
| Vol. 18 No. 3 |
United States Pharmacopeia Chapter <922> Water Activity
|
| Vol. 18 No. 2 |
IJPC January/February 2021 Table of Contents
|
| Vol. 18 No. 1 |
Editor's Announcement
|
| Vol. 17 No. 50 |
Merry Christmas from IJPC
|
| Vol. 17 No. 49 |
"QS" your IJPC Journal Collection With Missing or Additional Issues
|
| Vol. 17 No. 48 |
"QS" your IJPC Journal Collection With Missing or Additional Issues
|
| Vol. 17 No. 47 |
Thanksgiving
|
| Vol. 17 No. 46 |
IJPC November/December 2020 Table of Contents
|
| Vol. 17 No. 45 |
NASEM Report: Part 17
|
| Vol. 17 No. 44 |
NASEM Report: Part 16
|
| Vol. 17 No. 43 |
NASEM Report: Part 15
|
| Vol. 17 No. 42 |
NASEM Report: Part 14
|
| Vol. 17 No. 41 |
NASEM Report: Part 13
|
| Vol. 17 No. 40 |
NASEM Report: Part 12
|
| Vol. 17 No. 39 |
NASEM Report: Part 11
|
| Vol. 17 No. 38 |
IJPC September/October 2020 Table of Contents
|
| Vol. 17 No. 37 |
NASEM Report: Part 10
|
| Vol. 17 No. 36 |
NASEM Report: Part 9
|
| Vol. 17 No. 35 |
NASEM Report: Part 8
|
| Vol. 17 No. 34 |
NASEM Report: Part 7
|
| Vol. 17 No. 33 |
NASEM Report: Part 6
|
| Vol. 17 No. 32 |
NASEM Report: Part 5
|
| Vol. 17 No. 31 |
NASEM Report: Part 4
|
| Vol. 17 No. 30 |
NASEM Report: Part 3
|
| Vol. 17 No. 29 |
NASEM Report: Part 2
|
| Vol. 17 No. 28 |
NASEM Report
|
| Vol. 17 No. 27 |
The Two NASEM Reports on Compounded Topical Pain Creams and Bioidentical Hormone Therapy
|
| Vol. 17 No. 26 |
IJPC July/August 2020 Table of Contents
|
| Vol. 17 No. 25 |
Hazardous Drugs
|
| Vol. 17 No. 24 |
Environmental Protection Agency, Part 14 (Final)
|
| Vol. 17 No. 23 |
Environmental Protection Agency, Part 13
|
| Vol. 17 No. 22 |
Environmental Protection Agency, Part 12
|
| Vol. 17 No. 21 |
Environmental Protection Agency, Part 11
|
| Vol. 17 No. 20 |
Environmental Protection Agency, Part 10
|
| Vol. 17 No. 19 |
Environmental Protection Agency, Part 9
|
| Vol. 17 No. 18 |
IJPC May/June 2020 Table of Contents
|
| Vol. 17 No. 17 |
Environmental Protection Agency, Part 8
|
| Vol. 17 No. 16 |
Considerations in a Global Pharmaceutical System (June 4, 2010)
|
| Vol. 17 No. 15 |
Environmental Protection Agency, Part 7
|
| Vol. 17 No. 14 |
Environmental Protection Agency, Part 6
|
| Vol. 17 No. 13 |
Environmental Protection Agency, Part 5
|
| Vol. 17 No. 12 |
Environmental Protection Agency, Part 4
|
| Vol. 17 No. 11 |
IJPC Mar/Apr 2020 - Table of Contents
|
| Vol. 17 No. 10 |
Environmental Protection Agency, Part 3
|
| Vol. 17 No. 9 |
Environmental Protection Agency, Part 2
|
| Vol. 17 No. 8 |
Environmental Protection Agency, Part 1
|
| Vol. 17 No. 7 |
OSHA (Occupational Safety and Health Administration), Part 10
|
| Vol. 17 No. 6 |
OSHA (Occupational Safety and Health Administration), Part 9
|
| Vol. 17 No. 5 |
OSHA (Occupational Safety and Health Administration), Part 8
|
| Vol. 17 No. 4 |
OSHA (Occupational Safety and Health Administration), Part 7
|
| Vol. 17 No. 3 |
OSHA (Occupational Safety and Health Administration), Part 6
|
| Vol. 17 No. 2 |
OSHA (Occupational Safety and Health Administration), Part 5
|
| Vol. 17 No. 1 |
IJPC Jan/Feb 2020 - Table of Contents
|
| Vol. 16 No. 50 |
Merry Christmas from the IJPC Staff!
|
| Vol. 16 No. 49 |
OSHA (Occupational Safety and Health Administration), Part 4: General Information and Permissible Exposure Limits
|
| Vol. 16 No. 48 |
OSHA (Occupational Safety and Health Administration), Part 3: Results and Appeals
|
| Vol. 16 No. 47 |
OSHA (Occupational Safety and Health Administration), Part 2: Inspection Process
|
| Vol. 16 No. 46 |
OSHA (Occupational Safety and Health Administration)
|
| Vol. 16 No. 45 |
IJPC Nov/Dec 2019 - Table of Contents
|
| Vol. 16 No. 44 |
The Role of NIOSH
|
| Vol. 16 No. 43 |
The Role of NIOSH
|
| Vol. 16 No. 42 |
The Role of NIOSH
|
| Vol. 16 No. 41 |
The Role of NIOSH
|
| Vol. 16 No. 40 |
Are We Regulated?
|
| Vol. 16 No. 39 |
USP Notice Published
|
| Vol. 16 No. 38 |
Further Appeal of USP Chapter Revisions
|
| Vol. 16 No. 37 |
IJPC Sep/Oct 2019 - Table of Contents
|
| Vol. 16 No. 36 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 35 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 34 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 33 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 32 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 31 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 30 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 29 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 28 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 27 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 26 |
IJPC Jul/Aug 2019 - Table of Contents
|
| Vol. 16 No. 25 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 24 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 23 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 22 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 21 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 20 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 19 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 18 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 17 |
IJPC May/Jun 2019 - Table of Contents
|
| Vol. 16 No. 16 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 15 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 14 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 13 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 12 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 11 |
IJPC March/April 2019 -
Table of Contents
|
| Vol. 16 No. 10 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 9 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 8 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 7 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 6 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 5 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 4 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 3 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 16 No. 2 |
IJPC January/February 2019 -
Table of Contents
|
| Vol. 16 No. 1 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 15 No. 51 |
Happy New Year from IJPC!
|
| Vol. 15 No. 50 |
Merry Christmas from IJPC
|
| Vol. 15 No. 49 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 15 No. 48 |
Pharmaceutical Compounding Questions and Answers
|
| Vol. 15 No. 47 |
APIs Used in Pharmaceutical Compounding
|
| Vol. 15 No. 46 |
USP <797>: Time for Comments!
|
| Vol. 15 No. 45 |
IJPC November/December 2018 - Table of Contents
|
| Vol. 15 No. 44 |
Draft Memorandum of Understanding-Round 3, Part 6 (Final)
|
| Vol. 15 No. 43 |
Draft Memorandum of Understanding-Round 3, Part 5
|
| Vol. 15 No. 42 |
Draft Memorandum of Understanding-Round 3, Part 4
|
| Vol. 15 No. 41 |
Draft Memorandum of Understanding-Round 3, Part 3
|
| Vol. 15 No. 40 |
Draft Memorandum of Understanding-Round 3, Part 2
|
| Vol. 15 No. 39 |
IJPC September/October 2018 Table of Contents
|
| Vol. 15 No. 38 |
Draft Memorandum of Understanding-Round 3, Part 1
|
| Vol. 15 No. 37 |
Standardization of Some Compounded Dosage Forms, Part 4
|
| Vol. 15 No. 36 |
Standardization of Some Compounded Dosage Forms, Part 3
|
| Vol. 15 No. 35 |
Standardization of Some Compounded Dosage Forms, Part 2
|
| Vol. 15 No. 34 |
Standardization of Some Compounded Dosage Forms
|
| Vol. 15 No. 33 |
Announcement for IJPC and CT.com Subscribers
|
| Vol. 15 No. 32 |
USP <797> Round Two
|
| Vol. 15 No. 31 |
Innovative Approaches for Nonprescription Drug Products—Guidance for Industry, Part 3
|
| Vol. 15 No. 30 |
Innovative Approaches for Nonprescription Drug Products—Guidance for Industry, Part 2
|
| Vol. 15 No. 29 |
Innovative Approaches for Nonprescription Drug Products—Guidance for Industry, Part 1
|
| Vol. 15 No. 28 |
Right to Try Act, Part 3
|
| Vol. 15 No. 27 |
Right to Try Act, Part 2
|
| Vol. 15 No. 26 |
Right to Try Act, Part 1
|
| Vol. 15 No. 25 |
Important Dates
|
| Vol. 15 No. 24 |
Coming in the July/August 2018 Issue of IJPC
|
| Vol. 15 No. 23 |
Nonsterile Preparations Water Activity BUDs
|
| Vol. 15 No. 22 |
<795> Pharmaceutical Compounding-Nonsterile Preparations
|
| Vol. 15 No. 21 |
<795> Pharmaceutical Compounding-Nonsterile Preparations
|
| Vol. 15 No. 20 |
<795> Pharmaceutical Compounding-Nonsterile Preparations
|
| Vol. 15 No. 19 |
<795> Pharmaceutical Compounding-Nonsterile Preparations
|
| Vol. 15 No. 18 |
<795> Pharmaceutical Compounding-Nonsterile Preparations
|
| Vol. 15 No. 17 |
<795> Pharmaceutical Compounding-Nonsterile Preparations
|
| Vol. 15 No. 16 |
<795> Pharmaceutical Compounding-Nonsterile Preparations
|
| Vol. 15 No. 15 |
Two Items Available for Your Comments
|
| Vol. 15 No. 14 |
Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal food, Drug, and Cosmetic Act
- Guidance for Industry
|
| Vol. 15 No. 13 |
Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act Comments: Part III
|
| Vol. 15 No. 12 |
Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act Comments: Part II
|
| Vol. 15 No. 11 |
Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Comments: Part I
|
| Vol. 15 No. 10 |
March/April 2018 Issue of IJPC
|
| Vol. 15 No. 9 |
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act—Guidance for Industry (January 2018) Part IV (Conclusion)
|
| Vol. 15 No. 8 |
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act—Guidance for Industry (January 2018) Part III
|
| Vol. 15 No. 7 |
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act—Guidance for Industry (January 2018) Part II
|
| Vol. 15 No. 6 |
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act—Guidance for Industry (January 2018)
Comments: Part I
|
| Vol. 15 No. 5 |
FDA 2018 Compounding Policy Priority Plan
|
| Vol. 15 No. 4 |
FDA 2018 Compounding Policy Priority Plan
|
| Vol. 15 No. 3 |
New Look for IJPC
|
| Vol. 15 No. 2 |
January/February 2018 Issue of IJPC
|
| Vol. 15 No. 1 |
What Will 2018 Bring? What Does the International Journal of Pharmaceutical Compounding Do to Assist and Support You?
|
| Vol. 14 No. 50 |
Merry Christmas
|
| Vol. 14 No. 49 |
From Out of the Past…Part V!
|
| Vol. 14 No. 48 |
From Out of the Past…Part IV!
|
| Vol. 14 No. 47 |
Compounding Advisory Committee Recommendations and Out of the Past Part III!
|
| Vol. 14 No. 46 |
November/December Issue of IJPC
|
| Vol. 14 No. 45 |
Find Out What's Going On!!!!
|
| Vol. 14 No. 44 |
From Out of the Past…Part II!
|
| Vol. 14 No. 43 |
From Out of the Past…Part I!
|
| Vol. 14 No. 42 |
Issues with the NAMS 2017 Hormone Therapy Position Statement, Part II
|
| Vol. 14 No. 41 |
Issues with the NAMS 2017 Hormone Therapy Position Statement, Part I
|
| Vol. 14 No. 40 |
IJPC eTOC Coming Soon
|
| Vol. 14 No. 39 |
The Biopharmaceutics Classification System (BCS) and Compounding: Part 12
|
| Vol. 14 No. 38 |
The Biopharmaceutics Classification System (BCS) and Compounding: Part 11
|
| Vol. 14 No. 37 |
The Biopharmaceutics Classification System (BCS) and Compounding: Part 10
|
| Vol. 14 No. 36 |
The Biopharmaceutics Classification System (BCS) and Compounding: Part 9
|
| Vol. 14 No. 35 |
The Biopharmaceutics Classification System (BCS) and Compounding: Part 8
|
| Vol. 14 No. 34 |
The Biopharmaceutics Classification System (BCS) and Compounding: Part 7
|
| Vol. 14 No. 33 |
The Biopharmaceutics Classification System (BCS) and Compounding: Part 6
|
| Vol. 14 No. 32 |
The Biopharmaceutics Classification System (BCS) and Compounding: Part 5
|
| Vol. 14 No. 31 |
The Biopharmaceutics Classification System (BCS) and Compounding: Part 4
|
| Vol. 14 No. 30 |
The Biopharmaceutics Classification System (BCS) and Compounding: Part 3
|
| Vol. 14 No. 29 |
The Biopharmaceutics Classification System (BCS) and Compounding: Part 2
|
| Vol. 14 No. 28 |
The Biopharmaceutics Classification System (BCS) and Compounding: Part 1
|
| Vol. 14 No. 27 |
Holiday Recap
|
| Vol. 14 No. 26 |
SOP for Evaluating Human-Use Sterilizing Filters (<797>)
|
| Vol. 14 No. 25 |
Pharmacogenomics and Compounding Pharmacists, Part XII
|
| Vol. 14 No. 24 |
More on Human-Use Sterilizing Filters (<797>)
|
| Vol. 14 No. 23 |
Human-Use Sterilizing Filters (<797>)
|
| Vol. 14 No. 22 |
Container-Closure Systems and Beyond-Use Dates
|
| Vol. 14 No. 21 |
Pharmacogenomics and Compounding Pharmacists, Part XI
|
| Vol. 14 No. 20 |
Pharmacogenomics and Compounding Pharmacists, Part X
|
| Vol. 14 No. 19 |
Pharmacogenomics and Compounding Pharmacists, Part IX
|
| Vol. 14 No. 18 |
Pharmacogenomics and Compounding Pharmacists, Part VIII
|
| Vol. 14 No. 17 |
"800" Alternative for State Boards of Pharmacy
|
| Vol. 14 No. 16 |
"800" Alternative for State Boards of Pharmacy
|
| Vol. 14 No. 15 |
Pharmacogenomics and Compounding Pharmacists, Part VII
|
| Vol. 14 No. 14 |
Pharmacogenomics and Compounding Pharmacists, Part VI
|
| Vol. 14 No. 13 |
Consensus Statement on the Handling of Hazardous Drugs per USP Chapter <800>
|
| Vol. 14 No. 12 |
Pharmacogenomics and Compounding Pharmacists, Part V
|
| Vol. 14 No. 11 |
Pharmacogenomics and Compounding Pharmacists, Part IV
|
| Vol. 14 No. 10 |
Pharmacogenomics and Compounding Pharmacists, Part III
|
| Vol. 14 No. 9 |
Pharmacogenomics and Compounding Pharmacists, Part II
|
| Vol. 14 No. 8 |
Pharmacogenomics and Compounding Pharmacists, Part I
|
| Vol. 14 No. 7 |
U.S. Food and Drug Administration (FDA) Compliance Policy Guidelines: 503A Draft Guidance for Industry
|
| Vol. 14 No. 6 |
U.S. Food and Drug Administration (FDA) Compliance Policy Guidelines: 503A Draft Guidance for Industry
|
| Vol. 14 No. 5 |
U.S. Food and Drug Administration (FDA) Compliance Policy Guidelines: 503A Draft Guidances
|
| Vol. 14 No. 4 |
U.S. Food and Drug Administration (FDA) Compliance Policy Guidelines: 503A Draft Guidances
|
| Vol. 14 No. 3 |
U.S. Food and Drug Administration (FDA) Compliance Policy Guidelines: 503A Draft Guidances
|
| Vol. 14 No. 2 |
U.S. Food and Drug Administration (FDA) Compliance Policy Guidelines: 503A Draft Guidances
|
| Vol. 14 No. 1 |
U.S. Food and Drug Administration (FDA) Compliance Policy Guidelines: 503A Draft Guidances
|
| Vol. 13 No. 51 |
Happy New Year from IJPC!
|
| Vol. 13 No. 50 |
Merry Christmas from IJPC!
|
| Vol. 13 No. 49 |
U.S. Food and Drug Administration (FDA) Compliance Policy Guidelines: 503A Draft Guidances
|
| Vol. 13 No. 48 |
U.S. Food and Drug Administration (FDA) Compliance Policy Guidelines: 503A Draft Guidances
|
| Vol. 13 No. 47 |
U.S. Food and Drug Administration (FDA) Compliance Policy Guidelines: 503A Draft Guidances
|
| Vol. 13 No. 46 |
U.S. Food and Drug Administration Compliance Policy Guidelines
|
| Vol. 13 No. 45 |
U.S. Food and Drug Administration Compliance Policy Guidelines
|
| Vol. 13 No. 44 |
U.S. Food and Drug Administration Compliance Policy Guidelines
|
| Vol. 13 No. 43 |
U.S. Food and Drug Administration Compliance Policy Guidelines
|
| Vol. 13 No. 42 |
U.S. Food and Drug Administration Compliance Guidelines
|
| Vol. 13 No. 41 |
U.S. Food and Drug Administration Compliance Policy Guidelines
|
| Vol. 13 No. 40 |
FDA Preemption Jurisprudence
|
| Vol. 13 No. 39 |
U.S. Food and Drug Administration Compliance Policy Guidelines, Part 3
|
| Vol. 13 No. 38 |
U.S. Food and Drug Administration Compliance Policy Guidelines, Part 2
|
| Vol. 13 No. 37 |
U.S. Food and Drug Administration Compliance Policy Guidelines, Part 1
|
| Vol. 13 No. 36 |
Announcement: Practice Standards Discussions Compiled Into One Free Download at CompoundingToday.com
|
| Vol. 13 No. 35 |
U.S. Food and Drug Administration “Import Alerts”, Part 3
|
| Vol. 13 No. 34 |
U.S. Food and Drug Administration “Import Alerts”, Part 2
|
| Vol. 13 No. 33 |
U.S. Food and Drug Administration “Import Alerts”, Part 1
|
| Vol. 13 No. 32 |
Stability Studies and United States Pharmacopeia–National Formulary-grade Chemicals
|
| Vol. 13 No. 31 |
U.S. Food and Drug Administration Compounding Pharmacy Inspection Procedures to Change
|
| Vol. 13 No. 30 |
United States Pharmacopeia and Professional Practice Standards: A Follow-up
|
| Vol. 13 No. 29 |
Implementing United States Pharmacopeia <800>, Part 23: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 28 |
Implementing United States Pharmacopeia <800>, Part 22: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 27 |
Implementing United States Pharmacopeia <800>, Part 21: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 26 |
Implementing United States Pharmacopeia <800>, Part 20: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 25 |
Implementing United States Pharmacopeia <800>, Part 19: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 24 |
Implementing United States Pharmacopeia <800>, Part 18: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 23 |
Does the United States Pharmacopeial Convention, Inc. Have the Authority to Establish “Official” Professional Practice Standards for Pharmacy, Medicine, Nursing, Etc?
|
| Vol. 13 No. 22 |
Implementing United States Pharmacopeia <800>, Part 17: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 21 |
Implementing United States Pharmacopeia <800>, Part 16: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 20 |
Implementing United States Pharmacopeia <800>, Part 15: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 19 |
Implementing United States Pharmacopeia <800>, Part 14: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 18 |
Implementing United States Pharmacopeia <800>, Part 13: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 17 |
Implementing United States Pharmacopeia <800>, Part 12: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 16 |
Implementing United States Pharmacopeia <800>, Part 11: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 15 |
Implementing United States Pharmacopeia <800>, Part 10: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 14 |
Implementing United States Pharmacopeia <800>, Part 9: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 13 |
Implementing United States Pharmacopeia <800>, Part 8: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 12 |
Implementing United States Pharmacopeia <800>, Part 7: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 11 |
Implementing United States Pharmacopeia <800>, Part 6: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 10 |
Implementing United States Pharmacopeia <800>, Part 5: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 9 |
Implementing United States Pharmacopeia <800>, Part 4: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 8 |
Implementing United States Pharmacopeia <800>, Part 3: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 7 |
Implementing United States Pharmacopeia <800>, Part 2: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 6 |
Implementing United States Pharmacopeia <800>, Part 1: Hazardous Drugs-Handling in Healthcare Settings
|
| Vol. 13 No. 5 |
Summary of ‘483s given to Registered Outsourcing Facilities, Part 9
|
| Vol. 13 No. 4 |
Summary of ‘483s given to Registered Outsourcing Facilities, Part 8
|
| Vol. 13 No. 3 |
Summary of ‘483s given to Registered Outsourcing Facilities, Part 7
|
| Vol. 13 No. 2 |
Summary of ‘483s given to Registered Outsourcing Facilities, Part 6
|
| Vol. 13 No. 1 |
Summary of ‘483s given to Registered Outsourcing Facilities, Part 5
|
| Vol. 12 No. 50 |
Summary of ‘483s given to Registered Outsourcing Facilities, Part 4
|
| Vol. 12 No. 49 |
Summary of ‘483s given to Registered Outsourcing Facilities, Part 3
|
| Vol. 12 No. 48 |
Summary of ‘483s given to Registered Outsourcing Facilities, Part 2
|
| Vol. 12 No. 47 |
Summary of ‘483s given to Registered Outsourcing Facilities
|
| Vol. 12 No. 46 |
Update on Registered Outsourcing Facilities
|
| Vol. 12 No. 45 |
Is There Any Basis for the FDA Disqualifying USP Dietary Supplements for Compounding? Part II
|
| Vol. 12 No. 44 |
Is There Any Basis for the FDA Disqualifying USP Dietary Supplements for Compounding? Part I
|
| Vol. 12 No. 43 |
Proposed <797> BUDs—Limited to 42 Days-Time Required to Perform USP <71> and USP <51> Tests: Valid?
|
| Vol. 12 No. 42 |
Proposed USP <797> BUDs Not Based on Science
|
| Vol. 12 No. 41 |
Clinical Pharmaceutics and Compounding, Part XL
|
| Vol. 12 No. 40 |
United States Pharmacopeia <797>, Round 3
|
| Vol. 12 No. 39 |
Clinical Pharmaceutics and Compounding, Part XXXIX
|
| Vol. 12 No. 38 |
Clinical Pharmaceutics and Compounding, Part XXXVIII
|
| Vol. 12 No. 37 |
Clinical Pharmaceutics and Compounding, Part XXXVII
|
| Vol. 12 No. 36 |
Science or Science Fiction? Show Me the Science! Question Everything!
|
| Vol. 12 No. 35 |
Clinical Pharmaceutics and Compounding, Part XXXVI
|
| Vol. 12 No. 34 |
Clinical Pharmaceutics and Compounding, Part XXXV
|
| Vol. 12 No. 33 |
FDA "Evaluation Criteria" for Difficult to Compound Drugs
|
| Vol. 12 No. 32 |
Nominations of Difficult to Compound Drugs to the FDA-PCAC
|
| Vol. 12 No. 31 |
Clinical Pharmaceutics and Compounding, Part XXXIV
|
| Vol. 12 No. 30 |
USP Compounding Expert Committee (CMP EC) Roster 2015-2020
|
| Vol. 12 No. 29 |
Clinical Pharmaceutics and Compounding, Part XXXIII
|
| Vol. 12 No. 28 |
Clinical Pharmaceutics and Compounding, Part XXXII
|
| Vol. 12 No. 27 |
The Declaration of Independence: Then and Now!
|
| Vol. 12 No. 26 |
Clinical Pharmaceutics and Compounding, Part XXXI
|
| Vol. 12 No. 25 |
USP <795> Revised Table on BUDs
|
| Vol. 12 No. 24 |
NIH Pharmacy: A Premier Model Pharmacy? Fungal Contamination and Insects Shuts Down the Facility
|
| Vol. 12 No. 23 |
What’s Happening on the Veterinary Compounding Front!
|
| Vol. 12 No. 22 |
Clinical Pharmaceutics and Compounding, Part XXX
|
| Vol. 12 No. 21 |
Clinical Pharmaceutics and Compounding, Part XXIX
|
| Vol. 12 No. 20 |
Clinical Pharmaceutics and Compounding, Part XXVIII
|
| Vol. 12 No. 19 |
Clinical Pharmaceutics and Compounding, Part XXVII
|
| Vol. 12 No. 18 |
Clinical Pharmaceutics and Compounding, Part XXVI
|
| Vol. 12 No. 17 |
Clinical Pharmaceutics and Compounding, Part XXV
|
| Vol. 12 No. 16 |
Clinical Pharmaceutics and Compounding, Part XXIV
|
| Vol. 12 No. 15 |
Clinical Pharmaceutics and Compounding, Part XXIII
|
| Vol. 12 No. 14 |
Clinical Pharmaceutics and Compounding, Part XXII
|
| Vol. 12 No 13 |
Clinical Pharmaceutics and Compounding, Part XXI
|
| Vol. 12 No. 12 |
Clinical Pharmaceutics and Compounding, Part XX
|
| Vol. 12 No. 11 |
Prescriptions for Compounded and Manufactured HRT Drugs Running Neck and Neck!
|
| Vol. 12 No. 10 |
Clinical Pharmaceutics and Compounding, Part XIX
|
| Vol. 12 No. 9 |
Clinical Pharmaceutics and Compounding, Part XVIII
|
| Vol. 12 No. 8 |
Clinical Pharmaceutics and Compounding, Part XVII
|
| Vol. 12 No. 7 |
Clinical Pharmaceutics and Compounding, Part XVI
|
| Vol. 12 No. 6 |
Clinical Pharmaceutics and Compounding, Part XV
|
| Vol. 12 No. 5 |
New CVS/Caremark Requirements for Contract Renewal
|
| Vol. 12 No. 4 |
Clinical Pharmaceutics and Compounding, Part XIV
|
| Vol. 12 No. 3 |
Clinical Pharmaceutics and Compounding, Part XIII
|
| Vol. 12 No. 2 |
Clinical Pharmaceutics and Compounding, Part XII
|
| Vol. 12 No. 1 |
Looking Back and Looking Ahead to 2015
|
| Vol. 11 No. 49 |
Merry Christmas!
|
| Vol. 11 No. 48 |
Clinical Pharmaceutics and Compounding, Part XI
|
| Vol. 11 No. 47 |
Where are we now? A survey may help us to know and plan for the future!
|
| Vol. 11 No. 46 |
Clinical Pharmaceutics and Compounding, Part X
|
| Vol. 11 No. 45 |
PBM Experience of a Compounding Pharmacist
|
| Vol. 11 No. 44 |
Clinical Pharmaceutics and Compounding, Part IX
|
| Vol. 11 No. 43 |
Clinical Pharmaceutics and Compounding, Part VIII
|
| Vol. 11 No. 42 |
Clinical Pharmaceutics and Compounding, Part VII
|
| Vol. 11 No. 41 |
Clinical Pharmaceutics and Compounding, Part VI
|
| Vol. 11 No. 40 |
Clinical Pharmaceutics and Compounding, Part V
|
| Vol. 11 No. 39 |
Clinical Pharmaceutics and Compounding, Part IV
|
| Vol. 11 No. 38 |
Clinical Pharmaceutics and Compounding, Part III
|
| Vol. 11 No. 37 |
Clinical Pharmaceutics and Compounding, Part II
|
| Vol. 11 No. 36 |
Clinical Pharmaceutics, Part I
|
| Vol. 11 No. 35 |
Finally! “Named Formulas” Database Available
|
| Vol. 11 No. 34 |
What is Compounding Pharmacy, XV: Summary
|
| Vol. 11 No. 33 |
What is Compounding Pharmacy, Part XIV: Site Presentation
|
| Vol. 11 No. 32 |
What is Compounding Pharmacy, Part XIII: Public Presentation(s)
|
| Vol. 11 No. 31 |
What is Compounding Pharmacy, Part XII: Integrity and Responsibility
|
| Vol. 11 No. 30 |
What is Compounding Pharmacy, Part XI: Patient Oriented
|
| Vol. 11 No. 29 |
What is Compounding
Pharmacy, Part X: Problem-solving
|
| Vol. 11 No. 28 |
What is Compounding Pharmacy, Part IX: Cutting Edge
|
| Vol. 11 No. 27 |
What is Compounding Pharmacy, Part VIII: Patient-centered
|
| Vol. 11 No. 26 |
What is Compounding Pharmacy, Part VII: Education and Training of a Compounding Pharmacist
|
| Vol. 11 No. 25 |
What is Compounding Pharmacy, Part VIb: Responsibilities of a Compounding Pharmacist
|
| Vol. 11 No. 24 |
What is Compounding Pharmacy, Part VIa: Responsibilities of a Compounding Pharmacist
|
| Vol. 11 No. 23 |
USP Web Meeting for General Chapter <800>
|
| Vol. 11 No. 22 |
What is Compounding Pharmacy, Part V: Meeting Patients' Needs
|
| Vol. 11 No. 21 |
What is Compounding Pharmacy, Part IV
|
| Vol. 11 No. 20 |
What is Compounding Pharmacy, Part III
|
| Vol. 11 No. 19 |
What is Compounding Pharmacy, Part II: Growth Factors
|
| Vol. 11 No. 18 |
What is Compounding Pharmacy, Part I
|
| Vol. 11 No. 17 |
USP Chapter <800> Applies to BOTH Dispensing and Compounding Pharmacies!
|
| Vol. 11 No. 16 |
My Creed
|
| Vol. 11 No. 15 |
Just Thinking about 503b…
|
| Vol. 11 No. 14 |
New USP <800> May Have Greater Impact than USP <797>
|
| Vol. 11 No. 13 |
Student Pharmacist Compounding Competition (SPCC) 2014: University of Colorado Skaggs School of Pharmacy Wins Overall
|
| Vol. 11 No. 12 |
"Inordinate amounts"; What does it mean?
|
| Vol. 11 No. 11 |
Difficult to Compound, Part III
|
| Vol. 11 No. 10 |
Difficult to Compound, Part II
|
| Vol. 11 No. 9 |
Difficult to Compound, Part I
|
| Vol. 11 No. 8 |
Is Just One List Feasible? Part II
|
| Vol. 11 No. 7 |
Is Just One List Feasible? Part I
|
| Vol. 11 No. 6 |
Definitions
|
| Vol. 11 No. 5 |
Definitions of Compounding
|
| Vol. 11 No. 4 |
FDA and the Advisory Committee on Compounding
|
| Vol. 11 No. 3 |
Summary Effects of H.R. 3204, Part II (503A)
|
| Vol. 11 No. 2 |
Quick Summary of H.R. 3204; Part I (503B)
|
| Vol. 11 No. 1 |
FDA Guidance Under 503B
|
| Vol. 10 No. 51 |
FDA Guidance Under 503a
|
| Vol. 10 No. 50 |
H.R. 3204 Drug Quality and Security Act
|
| Vol. 10 No. 49 |
What is Section 503A?
|
| Vol. 10 No. 48 |
It's "Déjà vu all over again"…but it's real!
|
| Vol. 10 No. 47 |
Polypill: Something New or History Recycling?
|
| Vol. 10 No. 46 |
Reflections: Lying and Politics! Truth and Trust?
|
| Vol. 10 No. 45 |
Drug Shortages 2013
|
| Vol. 10 No. 44 |
New Series in the International Journal of Pharmaceutical Compounding Beginning January/February 2014!
|
| Vol. 10 No. 43 |
Follow-up on Augmented Reality for Readers and Authors
|
| Vol. 10 No. 42 |
New Experience at IJPC: A First in Pharmacy Publishing!
|
| Vol. 10 No. 41 |
Changing Priorities
|
| Vol. 10 No. 40 |
Student Pharmacist Compounding Competition
|
| Vol. 10 No. 39 |
Disinfectants, Part I
|
| Vol. 10 No. 38 |
United States Pharmacopeia Chapter <51> Antimicrobial Effectiveness Testing
|
| Vol. 10 No. 37 |
Assigning Extended Beyond-Use-Dates
|
| Vol. 10 No. 36 |
Three Default Beyond-use Dates in United States Pharmacopeia Chapters <795> and <797>
|
| Vol. 10 No. 35 |
Sterility Testing
|
| Vol. 10 No. 34 |
Depyrogenation Methods
|
| Vol. 10 No. 33 |
The price of a life and pharmacy education?
|
| Vol. 10 No. 32 |
How Things Change! A Follow up.
|
| Vol. 10 No. 31 |
How things change!
|
| Vol. 10 No. 30 |
Documentation vs Opinion on Compounding Regulatory Activities XII
|
| Vol. 10 No. 29 |
Documentation vs Opinion on Compounding Regulatory Activities XI
|
| Vol. 10 No. 28 |
Documentation vs Opinion on Compounding Regulatory Activities X
|
| Vol. 10 No. 27 |
Documentation vs Opinion on Compounding Regulatory Activities IX
|
| Vol. 10 No. 26 |
Documentation vs Opinion on Compounding Regulatory Activities VIII
|
| Vol. 10 No. 25 |
Documentation vs Opinion on Compounding Regulatory Activities VII
|
| Vol. 10 No. 24 |
Documentation vs Opinion on Compounding Regulatory Activities VI
|
| Vol. 10 No. 23 |
Documentation vs Opinion on Compounding Regulatory Activities V
|
| Vol. 10 No. 22 |
New Addition to CompoundingToday.com
|
| Vol. 10 No. 21 |
Documentation vs Opinion on Compounding Regulatory Activities IV
|
| Vol. 10 No. 20 |
Documentation vs Opinion on Compounding Regulatory Activities III
|
| Vol. 10 No. 19 |
Documentation vs Opinion on Compounding Regulatory Activities II
|
| Vol. 10 No. 18 |
Documentation vs Opinion on Compounding Regulatory Activities I
|
| Vol. 10 No. 17 |
Current Good Manufacturing Practice (cGMP) Regulations, Part 13
|
| Vol. 10 No. 16 |
Current Good Manufacturing Practice (cGMP) Regulations, Part 12
|
| Vol. 10 No. 15 |
Current Good Manufacturing Practice (cGMP) Regulations, Part 11
|
| Vol. 10 No. 14 |
Current Good Manufacturing Practice (cGMP) Regulations, Part 10
|
| Vol. 10 No. 13 |
Current Good Manufacturing Practice (cGMP) Regulations, Part 9
|
| Vol. 10 No. 12 |
Current Good Manufacturing Practice (cGMP) Regulations, Part 8
|
| Vol. 10 No. 11 |
Current Good Manufacturing Practice (cGMP) Regulations, Part 7
|
| Vol. 10 No. 10 |
Current Good Manufacturing Practice (cGMP) Regulations, Part 6
|
| Vol. 10 No. 9 |
Differentiating "Manufacturing" from "Compounding"!
|
| Vol. 10 No. 8 |
Current Good Manufacturing Practice (cGMP) Regulations, Part 5
|
| Vol. 10 No. 7 |
It Just Doesn't Fit!
|
| Vol. 10 No. 6 |
Current Good Manufacturing Practice (cGMP) Regulations, Part 4
|
| Vol. 10 No. 5 |
Current Good Manufacturing Practice (cGMP) Regulations, Part 3
|
| Vol. 10 No. 4 |
Current Good Manufacturing Practice (cGMP) Regulations, Part 2
|
| Vol. 10 No. 3 |
Current Good Manufacturing Practice (cGMP) Regulations, Part 1
|
| Vol. 10 No. 2 |
Medication Use in the United States in 2011
|
| Vol. 10 No. 1 |
Another Year at the International Journal of Pharmaceutical Compounding
|
| Vol. 9 No. 50 |
Repackaging Sterile and Nonsterile Products-Some Tidbits
|
| Vol. 9 No. 49 |
Repackaging Nonsterile Products - Part 3
|
| Vol. 9 No. 48 |
Repackaging Nonsterile Products - Part 2
|
| Vol. 9 No. 47 |
Repackaging Nonsterile Products
|
| Vol. 9 No. 46 |
Repackaging Sterile Products-Another Scenario
|
| Vol. 9 No. 45 |
Repackaging Sterile Products
|
| Vol. 9 No. 44 |
To Verify or to Validate…that is the Question!
|
| Vol. 9 No. 43 |
Misrepresentations by the Press
|
| Vol. 9 No. 42 |
Are Our Pharmacy Leaders Missing an Opportunity?
|
| Vol. 9 No. 41 |
Compounding Pharmacists…Thank you!
|
| Vol. 9 No. 40 |
Another Tragic Situation!
|
| Vol. 9 No. 39 |
IJPC Achieves Another Milestone: MEDLINE
|
| Vol. 9 No. 38 |
CE Record-keeping Options: Look at the Details!
|
| Vol. 9 No. 37 |
"Bioidentical" Drugs are Written by ALL Prescribers!
|
| Vol. 9 No. 36 |
Political Conventions: Time for a change?
|
| Vol. 9 No. 35 |
It’s Football Time Again!
|
| Vol. 9 No. 34 |
Defining "Politics"
|
| Vol. 9 No. 33 |
Reimbursement Discrimination
|
| Vol. 9 No. 32 |
Supporting Each Other
|
| Vol. 9 No. 31 |
Pharmacy and the Olympics
|
| Vol. 9 No. 29 |
Where did it come from and how good is it?
|
| Vol. 9 No. 28 |
Liar, Liar, Pants on Fire!
|
| Vol. 9 No. 30 |
The "Dog Days" of Summer
|
| Vol. 9 No. 27 |
It’s time to help colleges refocus their curriculum!
|
| Vol. 9 No. 26 |
CMS Clarifies Position on Single-Dose Vials
|
| Vol. 9 No. 25 |
Those Difficult Professors…Friend or Fiend?
|
| Vol. 9 No. 24 |
Pharmacy Students Compounding Sterile Preparations in Experiential Practice Sites
|
| Vol. 9 No. 23 |
The Idea Light Bulb!
|
| Vol. 9 No. 22 |
United States Pharmacopeia 101, Part X
|
| Vol. 9 No. 21 |
United States Pharmacopeia 101, Part IX
|
| Vol. 9 No. 20 |
United States Pharmacopeia 101, Part VIII
|
| Vol. 9 No. 19 |
United States Pharmacopeia 101, Part VII
|
| Vol. 9 No. 18 |
United States Pharmacopeia 101, Part VI
|
| Vol. 9 No. 17 |
United States Pharmacopeia 101, Part V
|
| Vol. 9 No. 16 |
United States Pharmacopeia 101, Part IV
|
| Vol. 9 No. 15 |
United States Pharmacopeia 101, Part III
|
| Vol. 9 No. 14 |
United States Pharmacopeia 101, Part II
|
| Vol. 9 No. 13 |
United States Pharmacopeia 101, Part I
|
| Vol. 9 No. 12 |
University of Oklahoma College of Pharmacy-Tulsa Campus Wins First Place at 2012 National Student Compounding Competition
|
| Vol. 9 No. 11 |
Blowin' in the Wind…
|
| Vol. 9 No. 10 |
Learning requires effort and work!
|
| Vol. 9 No. 9 |
Smidgen, pinch, dash, tad, drop, and hint
|
| Vol. 9 No. 8 |
Looking Forward 2012, Part VII: DEA Harming Patients
|
| Vol. 9 No. 6 |
Looking Forward 2012, Part V
|
| Vol. 9 No. 7 |
Looking Forward 2012, Part VI-Service Pays Off!
|
| Vol. 9 No. 5 |
Looking Forward 2012, Part IV
|
| Vol. 9 No. 4 |
Looking Forward 2012, Part III
|
| Vol. 9 No. 3 |
Looking Forward 2012, Part II
|
| Vol. 9 No. 2 |
Looking Forward 2012, Part I
|
| Vol. 9 No. 1 |
Suggestions for the Political Process
|
| Vol. 8 No. 51 |
Welcome 2012-Are You Better Off?
|
| Vol. 8 No. 50 |
"A great present for U.S. taxpayers for 2011"?
|
| Vol. 8 No. 49 |
Faith, Fact, and Fantasy
|
| Vol. 8 No. 48 |
ASHP Clinical Midyear Lacks Compounding Programming
|
| Vol. 8 No. 47 |
Just Wondering, Where Does All the Money Go?
|
| Vol. 8 No. 46 |
NIH Pediatric Formulations Seminar
|
| Vol. 8 No. 45 |
More on the United States Pharmacopeia General Notices, Part X
|
| Vol. 8 No. 44 |
More on the United States Pharmacopeia General Notices, Part IX
|
| Vol. 8 No. 43 |
More on the United States Pharmacopeia General Notices, Part VIII
|
| Vol. 8 No. 42 |
More on the United States Pharmacopeia General Notices, Part VI
|
| Vol. 8 No. 41 |
More on the United States Pharmacopeia General Notices, Part VI
|
| Vol. 8 No. 40 |
More on the United States Pharmacopeia General Notices, Part V
|
| Vol. 8 No. 39 |
More on the United States Pharmacopeia General Notices, Part IV
|
| Vol. 8 No. 38 |
More on the United States Pharmacopeia General Notices, Part III
|
| Vol. 8 NO. 37 |
Court Decision Supports Compounding
|
| Vol. 8 No. 36 |
More on the United States Pharmacopeia General Notices, Part II
|
| Vol. 8 No. 35 |
More on the United States Pharmacopeia General Notices, Part I
|
| Vol. 8 No. 34 |
What is "about" all about?
|
| Vol. 8 No. 33 |
USP Salt and Base Nomenclature, Part 2
|
| Vol. 8 No. 32 |
Salt and Base Nomenclature
|
| Vol. 8 No. 31 |
Principles, Values, and Compromise
|
| Vol. 8 No. 30 |
Jumping into New Markets!
|
| Vol. 8 No. 29 |
Deceptive Practices
|
| Vol. 8 No. 28 |
Fact vs Opinion
|
| Vol. 8 No. 27 |
Lies and Lying!
|
| Vol. 8 No. 26 |
Freedom Only Works with Responsibility
|
| Vol. 8 No. 25 |
"The Priceless Ingredient"
|
| Vol. 8 No. 24 |
IACP CCH 2011 - A Great Meeting
|
| Vol. 8 No. 23 |
Johnny Cash and the National Debt
|
| Vol. 8 No. 22 |
Disappointment, Disillusionment, Disgust!
|
| Vol. 8 No. 21 |
Fraidy Holes
|
| Vol. 8 No. 20 |
Keeping up with Science and Technology!
|
| Vol. 8 No. 19 |
Commercials or Programs?
|
| Vol. 8 No. 18 |
Pharmacists and Retirement
|
| Vol. 8 No. 17 |
Expiration Dates, Drug Waste and Pollution
|
| Vol. 8 No. 16 |
Data Related to the Extent of Compounding
|
| Vol. 8 No. 15 |
Three National Pharmacy Meetings in Three Weeks
|
| Vol. 8 No. 14 |
“Do it right!” vs “Just do it!”
|
| Vol. 8 No. 13 |
17P, Makena and Compounding: Not an April Fools Joke!
|
| Vol. 8 No. 12 |
Insurance Plans Support Hydroxyprogesterone Caproate Compounding
|
| Vol. 8 No. 11 |
If it ain't broke, don't fix it!
|
| Vol. 8 No. 10 |
I’m on my way!
|
| Vol. 8 No. 9 |
Does a "Limited Distribution System" fit the definition of "Commercially Available"?
|
| Vol. 8 No. 8 |
What happened?
|
| Vol. 8 No. 7 |
What Do You Sell?
|
| Vol. 8 No. 6 |
Affiliation Agreement Reached between IJPC and IACP
|
| Vol. 8 No. 5 |
Discontinued Drugs
|
| Vol. 8 No. 4 |
Drug Shortages
|
| Vol. 8 No. 3 |
Two Inter-related Stories
|
| Vol. 8 No. 2 |
Small but Powerful! Auxiliary Labels
|
| Vol. 8 No. 1 |
"...but the fact of the matter is…"
|
| Vol. 7 No. 52 |
Crossroads or Crosshairs?
|
| Vol. 7 No. 51 |
Take Time...
|
| Vol. 7 No. 50 |
Changes in Compounders' Network List
|
| Vol. 7 No. 49 |
ASHP 2010
|
| Vol. 7 No. 48 |
Sense, Common Sense, Horse Sense: Are We Using It?
|
| Vol. 7 No. 47 |
Thanksgiving
|
| Vol. 7 No. 46 |
Changes and Opportunities
|
| Vol. 7 No. 45 |
Travel Tips: It's That Time of the Year
|
| Vol. 7 No. 44 |
Musings on the "V-O-T-E"
|
| Vol. 7 No. 43 |
Informative Response from Greece
|
| Vol. 7 No. 42 |
What others are teaching our children!
|
| Vol. 7 No. 41 |
Isn't It Great!
|
| Vol. 7 No. 40 |
ACA Meeting
|
| Vol. 7 No. 39 |
Documentation of Potential Problems in Compounding with Manufactured Products
|
| Vol. 7 No. 38 |
Possible Answers to Some Questions
|
| Vol. 7 No. 37 |
Insurance Company Discrimination, Revisited-Time for a Class Action?
|
| Vol. 7 No. 36 |
A Day to Celebrate the Worker!
|
| Vol. 7 No. 35 |
I Remember When…The American Dream
|
| Vol. 7 No. 34 |
Business Approach to Government
|
| Vol. 7 No. 33 |
Thoughts about Health Professionals
|
| Vol. 7 No. 32 |
Dog Days are Here
|
| Vol. 7 No. 31 |
Paper or Plastic? Paper or Digital?
|
| Vol. 7 No. 30 |
Are we really where we want to be?
|
| Vol. 7 No. 29 |
Compounding with Hazardous Drugs
|
| Vol. 7 No. 28 |
Planning!
|
| Vol. 7 No. 27 |
Independence Day
|
| Vol. 7 No. 26 |
Approved, Unapproved, Legal, and Illegal Drugs
|
| Vol. 7 No. 25 |
Use Most Current Information
|
| Vol. 7 No. 24 |
Should Pharmacy Depend Upon Governmental Programs?
|
| Vol. 7 No. 23 |
Considerations in a Global Pharmaceutical System
|
| Vol. 7 No. 22 |
Spring Cleaning
|
| Vol. 7 No. 21 |
Graduation Time of the Year
|
| Vol. 7 No. 20 |
Catch-22: FDA-CPG on Veterinary Compounding
|
| Vol. 7 No. 19 |
USP Compounding Resolution 8 Information
|
| Vol. 7 No. 18 |
USP Convention Follow-up
|
| Vol. 7 No. 17 |
2010 USP Convention
|
| Vol. 7 No. 16 |
NHIA 2010 Annual Meeting
|
| Vol. 7 No. 15 |
Balance: It's Important
|
| Vol. 7 No. 14 |
Higher Standards…Athletes or the U.S. Congress?
|
| Vol. 7 No. 13 |
BS + Internship or PharmD (Both 6 years of training to become a licensed pharmacist)
|
| Vol. 7 No. 12 |
Don’t you just love “elitism”!
|
| Vol. 7 No. 11 |
Spring Forward!
|
| Vol. 7 No. 10 |
Does the end justify the means?
|
| Vol. 7 No. 9 |
Communications
|
| Vol. 7 No. 8 |
Presidents' Day and Washington's Birthday: Which is Which?
|
| Vol. 7 No. 7 |
Valentine's Day! Who/What Are We Celebrating?
|
| Vol. 7 No. 6 |
Quality Improvement in Pharmaceutical Compounding
|
| Vol. 7 No. 5 |
Thinking About Tomorrow!
|
| Vol. 7 No. 4 |
Working Together
|
| Vol. 7 No. 3 |
Confusing Rules with Principles
|
| Vol. 7 No. 2 |
Cowboy Ethics Revisited: What Has Happened to Our Culture?
|
| Vol. 7 No. 1 |
Happy New Year!
|
| Vol. 6 No. 50 |
Merry Christmas!
|
| Vol. 6 No. 49 |
A Profession or a Job
|
| Vol. 6 No. 48 |
The U.S. Healthcare System is NOT “Broken”!
|
| Vol. 6 No. 47 |
Thanksgiving
|
| Vol. 6 No. 46 |
Media and Political Manipulation: Who is Manipulating Whom?
|
| Vol. 6 No. 45 |
Tamiflu Suspension Revisited
|
| Vol. 6 No. 44 |
Are these still in effect? Part 2
|
| Vol. 6 No. 43 |
Are these still in effect? Part 1
|
| Vol. 6 No. 42 |
2009 NCPA Program Sessions on Compounding in New Orleans
|
| Vol. 6 No. 41 |
Thyroid and Tamiflu!
|
| Vol. 6 No. 40 |
The 2009 H1N1 Flu, the Media, and the RxTriad
|
| Vol. 6 No. 39 |
Aging
|
| Vol. 6 No. 38 |
Melamine is Back!
|
| Vol. 6 No. 37 |
Drug Product Shortages: Opportunities for Compounding
|
| Vol. 6 No. 36 |
Labor Day: How it Came About; What it Means
|
| Vol. 6 No. 35 |
False Economy? Think before you act!
|
| Vol. 6 No. 34 |
Privacy vs Need to Know: How far do we put our trust?
|
| Vol. 6 No. 33 |
Basis for decisions: Documentation and/or judgment
|
| Vol. 6 No. 32 |
Snippets!
|
| Vol. 6 No. 31 |
Let's make a deal!
|
| Vol. 6 No. 30 |
Believe it or not!
|
| Vol. 6 No. 29 |
The Age of Communications for the Ages
|
| Vol. 6 No. 28 |
Florida Pharmacists Association Annual Meeting 2009
|
| Vol. 6 No. 27 |
We're All In This Together!
|
| Vol. 6 No. 26 |
Compounders on Capitol Hill a Great Success
|
| Vol. 6 No. 25 |
Trends in Drug Shortages; Opportunities for Compounding, Part 2
|
| Vol. 6 No. 24 |
Trends in Drug Shortages; Opportunities for Compounding, Part 1
|
| Vol. 6 No. 23 |
Quality Assurance of Parenteral Preparations
|
| Vol. 6 No. 22 |
Automatons
|
| Vol. 6 No. 21 |
Wyeth is at it again! Women are being cheating of estriol and Medicaid of millions of dollars
|
| Vol. 6 No. 20 |
Quality Assurance of Special Hard Gelatin Capsules
|
| Vol. 6 No. 19 |
Compounding Around the World
|
| Vol. 6 No. 18 |
Quality Assurance of Suppositories, Troches, Lollipops, and Sticks
|
| Vol. 6 No. 17 |
Quality Control, Quality Assurance and Quality Improvement-What is the Difference and Why Should You Care?
|
| Vol. 6 No. 16 |
Going backwards?
|
| Vol. 6 No. 15 |
Quality Assurance of Ointments, Creams, and Gels
|
| Vol. 6 No. 14 |
Quality Assurance of Oral and Topical Liquids
|
| Vol. 6 No. 13 |
Quality Assurance of Powder-Filled, Hard-Gelatin Capsules
|
| Vol. 6 No. 12 |
Is it realistic to think that through the government…
|
| Vol. 6 No. 11 |
INFARMA 2009
|
| Vol. 6 No. 10 |
Life, Liberty, and the Pursuit of Happiness OR ...
|
| Vol. 6 No. 9 |
States of Matter; States of States!
|
| Vol. 6 No. 8 |
Back to the Basics!
|
| Vol. 6 No. 7 |
My Two Cents!
|
| Vol. 6 No. 6 |
Discussion of Data and Demeanor
|
| Vol. 6 No. 5 |
Insurance Discrimination! Time for a Class Action xyzxyz?
|
| Vol. 6 No. 4 |
Things are Changing!
|
| Vol. 6 No. 3 |
Change!
|
| Vol. 6 No. 2 |
The Blind Leading the Blind; Let’s Open Their Eyes
|
| Vol. 6 No. 1 |
Resolutions Anyone?
|
| Vol. 5 No. 49 |
It's Hard to Believe!
|
| Vol. 5 No. 48 |
Economic Correction May Be What We Need
|
| Vol. 5 No. 47 |
Lack of Discipline or Circumstances: What is the Cause?
|
| Vol. 5 No. 46 |
Thanksgiving
|
| Vol. 5 No. 45 |
Isn't it interesting that...
|
| Vol. 5 No. 44 |
A lot of "bellyaching" going on this past year!
|
| Vol. 5 No. 43 |
“New Drug,” Labeling, and Label Responsibility
|
| Vol. 5 No. 42 |
Stress
|
| Vol. 5 No. 41 |
Should Black-Box Warnings be Dispensed with Commercial Prescriptions?
|
| Vol. 5 No. 40 |
Are we there yet?
|
| Vol. 5 No. 39 |
Misdirection
|
| Vol. 5 No. 38 |
Compounding Around the World!
|
| Vol. 5 No. 37 |
"Reporters" or "Political Activists"
|
| Vol. 5 No. 36 |
8-Tracks for Sale
|
| Vol. 5 No. 35 |
The Politics of Change
|
| Vol. 5 No. 34 |
AMA Action on Non-FDA-Approved Compounded Medications
|
| Vol. 5 No. 33 |
Dumb, Dumber, and Dumbest!
|
| Vol. 5 No. 32 |
Healthcare Reform: Different Things to Different People
|
| Vol. 5 No. 31 |
Cephalosporin Extra-Label Use to be Banned
|
| Vol. 5 No. 30 |
Standardized Formulas
|
| Vol. 5 No. 29 |
"New Drug", "Labeling" and the Midland Decision
|
| Vol. 5 No. 28 |
“Compounding Around the World”
|
| Vol. 5 No. 27 |
Who Owns the United States?
|
| Vol. 5 No. 26 |
Two Little Words
|
| Vol. 5 No. 25 |
Should the Government and Insurance Companies Pay for "Lifestyle" Drugs?
|
| Vol. 5 No. 24 |
DTC Advertising!
|
| Vol. 5 No. 23 |
IJPC-APhA Strategic Alliance
|
| Vol. 5 No. 22 |
It's Here—USP Chapter <797> is Official
|
| Vol. 5 No. 21 |
Lookin’, Learnin’, and Lobbyin’ at CCH 2008
|
| Vol. 5 No. 20 |
Made in the USA
|
| Vol. 5 No. 19 |
Twelve "Whereas's" and 1 "Be it Resolved"!
|
| Vol. 5 No. 18 |
Have We Learned Our Lesson Yet?
|
| Vol. 5 No. 17 |
USP Chapter <797> Question of the Week
|
| Vol. 5 No. 16 |
USP Chapter <797> Frequently Asked Questions
|
| Vol. 5 No. 15 |
No recourse for patients and consumers!
|
| Vol. 5 No. 14 |
USP Chapter <797> Workshop #1
|
| Vol. 5 No. 13 |
Examinations for Students on Rotations?
|
| Vol. 5 No. 12 |
FDA Losing Credibility
|
| Vol. 5 No. 11 |
My Drug Problem (Anonymous Submission)
|
| Vol. 5 No. 10 |
Who's running the country?
|
| Vol. 5 No. 9 |
Change: One of the constants of the universe!
|
| Vol. 5 No. 8 |
Ethiopia Project
|
| Vol. 5 No. 7 |
Double Standards
|
| Vol. 5 No. 6 |
Eleven Rules of Life
|
| Vol. 5 No. 5 |
Opinions and Convictions: Who are you?
|
| Vol. 5 No. 4 |
FDA, Wyeth, and Global Harmonization
|
| Vol. 5 No. 3 |
Educate Your Patients about “Unapproved Drugs"
|
| Vol. 5 No. 2 |
Déjà vu all over again!
|
| Vol. 5 No. 1 |
A New Year with Opportunities and Challenges
|
| Vol. 4 No. 51 |
Who do you want to be today? Makeovers!
|
| Vol. 4 No. 50 |
Avastin: Packaging, Repackaging, or Prepackaging?
|
| Vol. 4 No. 49 |
Musings on the Length of Pharmacy Education
|
| Vol. 4 No. 48 |
Revised USP Chapter <797>...Now Available!
|
| Vol. 4 No. 47 |
Am I Missing Something Here!
|
| Vol. 4 No. 46 |
Avastin, Genentech, and Particulate Matter
|
| Vol. 4 No. 45 |
Politics and Truth: An Emulsion or Solution?
|
| Vol. 4 No. 44 |
Avastin Update
|
| Vol. 4 No. 43 |
12th Spanish Congress of Compounding Pharmacy
|
| Vol. 4 No. 42 |
Incredible!!!!
|
| Vol. 4 No. 41 |
HEADLINE: Prescription Drugs Unavailable!
|
| Vol. 4 No. 40 |
IJPC-What it is!
|
| Vol. 4 No. 39 |
Health Insurance: Who should pay?
|
| Vol. 4 No. 38 |
Discrimination Towards Patients by Insurance Companies!
|
| Vol. 4 No. 37 |
Professional Terminology
|
| Vol. 4 No. 36 |
Truth vs Opinion
|
| Vol. 4 No. 35 |
Truth, Justice, and the American Way!
|
| Vol. 4 No. 34 |
Decimal Points and Units
|
| Vol. 4 No. 33 |
Free Prescriptions-What's Wrong with this Picture?
|
| Vol. 4 No. 32 |
Looking At or Looking Up To!
|
| Vol. 4 No. 31 |
Adverse Event Reporting in Compounding
|
| Vol. 4 No. 30 |
Two Good Questions
|
| Vol. 4 No. 29 |
Multi-State Annual Pharmacy Association Meetings
|
| Vol. 4 No. 28 |
Best Ever IACP Compounders on Capitol Hill!
|
| Vol. 4 No. 27 |
The White Coats are Coming!
|
| Vol. 4 No. 26 |
Freedom!
|
| Vol. 4 No. 25 |
Off-Label Uses of Drugs
|
| Vol. 4 No. 24 |
Quality Assurance in Compounding, Part XII
|
| Vol. 4 No. 23 |
Quality Assurance in Compounding, Part XI
|
| Vol. 4 No. 22 |
Quality Assurance in Compounding, Part X
|
| Vol. 4 No. 21 |
Quality Assurance in Compounding, Part IX
|
| Vol. 4 No. 20 |
Quality Assurance in Compounding, Part VIII
|
| Vol. 4 No. 19 |
Quality Assurance in Compounding, Part VII
|
| Vol. 4 No. 18 |
Pharmaceuticals and the Internet
|
| Vol. 4 No. 17 |
Quality Assurance in Compounding, Part VI
|
| Vol. 4 No. 16 |
Quality Assurance in Compounding, Part V
|
| Vol. 4 No. 15 |
Quality Assurance in Compounding, Part IV
|
| Vol. 4 No. 14 |
Quality Assurance in Compounding, Part III
|
| Vol. 4 No. 13 |
The Shell Game
|
| Vol. 4 No. 12 |
Quality Assurance in Compounding, Part II
|
| Vol. 4 No. 11 |
Quality Assurance in Compounding, Part I
|
| Vol. 4 No. 10 |
Who's the Criminal?
|
| Vol. 4 No. 9 |
Sphere of Influence
|
| Vol. 4 No. 8 |
The International Journal of Pharmaceutical Compounding—More Than a Journal
|
| Vol. 4 No. 7 |
FDA is Generating Income and Patients Lose Again
|
| Vol. 4 No. 6 |
How do I Select a Good Compounding Pharmacy?
|
| Vol. 4 No. 5 |
It Just Doesn't Calculate!
|
| Vol. 4 No. 4 |
I Don't Really Care About Apathy.
|
| Vol. 4 No. 3 |
Misrepresentations!
|
| Vol. 4 No. 2 |
Here We Go Again!
|
| Vol. 4 No. 1 |
Overs!
|
| Vol. 3 No. 52 |
Change!
|
| Vol. 3 No. 51 |
Pharmacy Compounding Accreditation Board Surveyors Trained
|
| Vol. 3 No. 50 |
The FDA vs the Federal Government
|
| Vol. 3 No. 49 |
Standard Operating Procedures, Part 2
|
| Vol. 3 No. 48 |
Standard Operating Procedures, Part 1
|
| Vol. 3 No. 47 |
The World's Largest College of Pharmacy
|
| Vol. 3 No. 46 |
Comments on the AMA Resolution
|
| Vol. 3 No. 45 |
Third-Party Payers Arbitrarily Discriminate
|
| Vol. 3 No. 44 |
Exhibit Halls at Meetings Reflect Changes
|
| Vol. 3 No. 43 |
Election time again!
|
| Vol. 3 No. 42 |
National Community Pharmacy Association (NCPA), Las Vegas, and Compounding
|
| Vol. 3 No. 41 |
Flak Jacket Not Required
|
| Vol. 3 No. 40 |
The Problem! Politicians and/or Bureaucrats?
|
| Vol. 3 No. 39 |
Quality Cannot be Tested into a Preparation, but, How Much is Enough?
|
| Vol. 3 No. 38 |
Compounding with Commercial Drugs Can Cause Errors!
|
| Vol. 3 No. 37 |
Big PHARMA and Misinformation!
|
| Vol. 3 No. 36 |
Why isn't everyone responsible?
|
| Vol. 3 No. 35 |
Federation of International Pharmacists (FIP) and the International Society of Pharmacy Compounding (ISPhC) Meetings in Brazil
|
| Vol. 3 No. 34 |
Drugmakers: Optimized for Failure?
|
| Vol. 3 No. 33 |
Second Pharmaceutical Compounding Quality Assurance Seminar
|
| Vol. 3 No. 32 |
Whatever Happened to Competition?
|
| Vol. 3 No. 31 |
Brand-Name Drug Companies Pay to Keep Generics Off the Market
|
| Vol. 3 No. 30 |
I Can't Believe It! Shake Well!
|
| Vol. 3 No. 29 |
Majority Suffers Because of the Minority!
|
| Vol. 3 No. 28 |
Personalized Medicine - Today!
|
| Vol. 3 No. 27 |
Support your pharmacy organizations!
|
| Vol. 3 No. 26 |
Headlines! Headlines! Headlines!
|
| Vol. 3 No. 25 |
Wyeth's FDA Warning letter of May 8, 2006; Part II
|
| Vol. 3 No. 24 |
Wyeth's FDA Warning letter of May 8, 2006; Part I
|
| Vol. 3 No. 23 |
AMA Resolution on Non-FDA-Approved Compounded Medications
|
| Vol. 3 No. 22 |
Pharmacy Compounding in Barcelona
|
| Vol. 3 No. 21 |
The Wyeth Petition, Part III: Are Today's Conjugated Estrogens "New Drugs"?
|
| Vol. 3 No. 20 |
Incomplete Labeling for Tacrolimus: Who is to Blame?
|
| Vol. 3 No. 19 |
The Wyeth Petition, Part II: It's Irrational!
|
| Vol. 3 No. 18 |
The Wyeth Petition, Part I: Is it Profits or Patients?
|
| Vol. 3 No. 17 |
Syringes must be used with care!
|
| Vol. 3 No. 16 |
Learning vs Education
|
| Vol. 3 No. 15 |
Kudos to the State of Mississippi
|
| Vol. 3 No. 14 |
First Pharmaceutical Compounding Quality Assurance Seminar
|
| Vol. 3 No. 13 |
Pharmacy Practice in France: Will it happen here in the US?
|
| Vol. 3 No. 12 |
European Association of Hospital Pharmacists in Geneva, Switzerland
|
| Vol. 3 No. 11 |
New Technology and Quality Control: Something New is Coming to Town
|
| Vol. 3 No. 10 |
I Don't Understand Why...
|
| Vol. 3 No. 9 |
Pharmacy Organizations: Do they Support You or Themselves?
|
| Vol. 3 No. 8 |
Patient Care Conflicts With Regulations, Laws, and Standards; AND Why do Insurance Companies Discriminate?
|
| Vol. 3 No. 7 |
Keep your paper copies!
|
| Vol. 3 No. 6 |
Kudos to IACP and the New Labeling Guidelines
|
| Vol. 3 No. 5 |
Corporate Greed!
|
| Vol. 3 No. 4 |
Talking to a Machine!
|
| Vol. 3 No. 3 |
"Specials" are not "Sale" Items in UK Pharmacies, Part II
|
| Vol. 3 No. 2 |
“Specials” are not “Sale” Items in UK Pharmacies, Part 1
|
| Vol. 3 No. 1 |
Where are the "statesmen"?
|
| Vol. 2 No. 50 |
Happy New Year
|
| Vol. 2 No. 49 |
Merry Christmas!
|
| Vol. 2 No. 48 |
Another Great Idea Gone Bad
|
| Vol. 2 No. 47 |
FDA and HHS National Leaders Support Individualized Medications!
|
| Vol. 2 No. 46 |
Orphan Drugs: Part II
|
| Vol. 2 No. 45 |
Orphan Drugs: Part I
|
| Vol. 2 No. 44 |
Acacia is Not Just Used in Drugs
|
| Vol. 2 No. 43 |
Unapproved Drugs, What's the big deal?
|
| Vol. 2 No. 42 |
Commercially Manufactured Bioidentical Hormones
|
| Vol. 2 No. 41 |
Chasing Rainbows? Part II
|
| Vol. 2 No. 40 |
Chasing Rainbows? Part I
|
| Vol. 2 No. 39 |
How do you keep up with pharmacy information?
|
| Vol. 2 No. 38 |
Overdosing the American Public? Compounding to the Rescue!
|
| Vol. 2 No. 37 |
Afraid to take responsibility?
|
| Vol. 2 No. 36 |
The FDA, Parenteral Drug Association (PDA) and Compounding for Clinical Studies
|
| Vol. 2 No. 35 |
Is "pharmacy" still a science-based profession?
|
| Vol. 2 No. 34 |
Kudos to the IJPC CNL and its' Moderator
|
| Vol. 2 No. 33 |
Priorities: First Three, Then Me!
|
| Vol. 2 No. 32 |
ACPE Requests Curriculum Content Input: Practicing Pharmacists Should Be Involved In Establishing Accreditation and Curriculum Standards, Part III
|
| Vol. 2 No. 31 |
ACPE Requests Curriculum Content Input: Practicing Pharmacists Should Be Involved In Establishing Accreditation and Curriculum Standards, Part II
|
| Vol. 2 No. 30 |
ACPE Requests Curriculum Content Input: Practicing Pharmacists Should Be Involved In Establishing Accreditation and Curriculum Standards, Part I
|
| Vol. 2 No. 29 |
The Seven Categories of Compounding
|
| Vol. 2 No. 28 |
The Impending Health Care System Crisis and Pharmaceuticals
|
| Vol. 2 No. 27 |
Beyond-Use Dates
|
| Vol. 2 No. 26 |
First Meeting of the USP Compounding Committees in the 2005-2010 Cycle
|
| Vol. 2 No. 25 |
Contemporary Topics in Pharmaceutical Compounding
|
| Vol. 2 No. 24 |
Freedom Celebration (including the freedom to compound)
|
| Vol. 2 No. 23 |
To Split or Not to Split-That is the Question: and the Answer is NO!!!!
|
| Vol. 2 No. 22 |
The New USP-Pharmacists' Pharmacopeia
|
| Vol. 2 No. 21 |
IACP-Compounders on Capitol Hill Meeting
|
| Vol. 2 No. 20 |
Should Pharmacists Handle Dangerous Chemicals
|
| Vol. 2 No. 19 |
USP-Part 6: General Questions and Comments
|
| Vol. 2 No. 18 |
USP-Part 5: Resolutions of the 2005 USP Convention, Concluded
|
| Vol. 2 No. 17 |
USP-Part 4: Resolutions of the 2005 USP Convention, Continued
|
| Vol. 2 No. 16 |
USP-Part 3: Resolutions of the 2005 USP Convention
|
| Vol. 2 No. 15 |
USP-Part 2: USP Expert Committee Procedures
|
| Vol. 2 No. 14 |
USP-Part 1: USP Compounding Pharmacy Expert Committees 2005-2010
|
| Vol. 2 No. 13 |
Four White Papers
|
| Vol. 2 No. 12 |
Find Out What You Don't Know
|
| Vol. 2 No. 11 |
The USP and its Support of Pharmaceutical Compounding
|
| Vol. 2 No. 10 |
Compounding “Unapproved New Drugs”
|
| Vol. 2 No. 9 |
Compounding For Office Use-Some Observations and Comments
|
| Vol. 2 No. 8 |
Affectors of Laboratory Results: Part VIII
|
| Vol. 2 No. 7 |
Affectors of Laboratory Results: Part VII
|
| Vol. 2 No. 6 |
Affectors of Laboratory Results: Part VI
|
| Vol. 2 No. 5 |
Affectors of Laboratory Results: Part V
|
| Vol. 2 No. 4 |
Affectors of Laboratory Results: Part IV
|
| Vol. 2 No. 3 |
Affectors of Laboratory Results: Part III
|
| Vol. 2 No. 2 |
Affectors of Laboratory Results: Part II
|
| Vol. 2 No. 1 |
Affectors of Laboratory Results: Part I
|
| Vol. 1 No. 6 |
The Science and Technology of Pharmaceutical Compounding...Worldwide (ISPhC)
|
| Vol. 1 No. 5 |
Systemic Anti-Inflammatories and Cardiac Problems
|
| Vol. 1 No. 4.1 |
Proposed Revisions to USP Chapter <797> Pharmaceutical Compounding - Sterile Preparations
|
| Vol. 1 No. 4 |
What a year for IJPC and compounding!
|
| Vol. 1 No. 3 |
Therapeutic Blood Levels
|
| Vol. 1 No. 2 |
USP-NF Grade Ingredients
|
| Vol. 1 No. 1 |
Introducing CompoundingToday.com
|
